Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7V2LG)

Drug Name
Chrysin Drug Info
Synonyms
chrysin; 480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5281607
ChEBI ID
CHEBI:75095
CAS Number
CAS 480-40-0
TTD Drug ID
DM7V2LG
VARIDT Drug ID
DR01258
INTEDE Drug ID
DR1939

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [8]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [9]
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [10]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [11]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [12]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [13]
Mycophenolate mofetil DMPQAGE Organ transplant rejection NE84 Approved [14]
Metronidazole DMTIVEN Amoebiasis 1A36 Approved [15]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [16]
Ethanol DMDRQZU Chronic pain MG30 Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [18]
Diclofenac DMPIHLS Osteoarthritis FA00-FA05 Approved [19]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [20]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [21]
Mycophenolate mofetil DMPQAGE Organ transplant rejection NE84 Approved [22]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [21]
Ibuprofen DM8VCBE Pain MG30-MG3Z Approved [21]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [23]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [21]
Haloperidol DM96SE0 Schizophrenia 6A20 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A8 (UGT1A8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Cutaneous T-cell lymphoma 2B01 Approved [24]
Empagliflozin DMRF9YK Type-1 diabetes 5A10 Approved [25]
Darolutamide DMV7YFT Prostate cancer 2C82.0 Approved [26]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Afimoxifene DMFORDT Breast cancer 2C60-2C65 Phase 2 [27]
Eugenol DM7US1H Discovery agent N.A. Patented [7]
Phloretin DMYA50U Discovery agent N.A. Investigative [7]
Anthraflavic acid DMN1YFU Discovery agent N.A. Investigative [7]
Cis-4-hydroxytamoxifen DMRFTB5 Discovery agent N.A. Investigative [27]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A7 (UGT1A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Cutaneous T-cell lymphoma 2B01 Approved [24]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [7]
Eugenol DM7US1H Discovery agent N.A. Patented [7]
Phloretin DMYA50U Discovery agent N.A. Investigative [7]
Anthraflavic acid DMN1YFU Discovery agent N.A. Investigative [7]
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Solid tumour/cancer 2A00-2F9Z Approved [28]
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [29]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [30]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [31]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [32]
Progesterone DMUY35B Premature labour JB00 Approved [33]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [34]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [33]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [35]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aromatase (CYP19A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anastrozole DMNP60F Breast cancer 2C60-2C65 Approved [37]
Letrozole DMH07Y3 Hormonally-responsive breast cancer 2C60-2C65 Approved [38]
Exemestane DM9HPW3 Hormonally-responsive breast cancer 2C60-2C65 Approved [38]
Aminoglutethimide DMWFHMZ Cushing disease 5A70 Approved [39]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [40]
Testolactone DMVY4GN Breast cancer 2C60-2C65 Approved [41]
Atamestane + Toremifene DM3QLK2 Breast cancer 2C60-2C65 Phase 3 [42]
LIAROZOLE DM4OYXE Dermatological disease DA24.Y Phase 2/3 [3]
Coumate DMVKW0N Breast cancer 2C60-2C65 Phase 2 [43]
Dextromethorphan+quinidine DMFI5J4 Diabetic neuropathy 8C0Z Phase 2 [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aldose reductase (AKR1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epalrestat DM5OGK0 Diabetic neuropathy 8C0Z Approved [45]
Sulindac DM2QHZU Rheumatoid arthritis FA20 Approved [46]
Fidarestat DMZL1I8 Diabetic complication 5A2Y Phase 3 [47]
Ranirestat DMD5QRS Diabetic neuropathy 8C0Z Phase 3 [48]
Contigoside B DMX9V8K Thrombosis DB61-GB90 Phase 2/3 [49]
BNV-222 DMYFQJL Diabetic neuropathy 8C0Z Phase 2/3 [50]
LIDORESTAT DMA0RI9 Diabetic complication 5A2Y Phase 2 [51]
QR-333 DMKVIWM Diabetic neuropathy 8C0Z Phase 2 [52]
ADMVA DM819CO Diabetic complication 5A2Y Phase 2 [48]
M-16209 DMZ7YX3 Diabetic complication 5A2Y Phase 2 [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [5]
Kaempferol DMHEMUB Discovery agent N.A. Investigative [5]
Morin DM2OGZ5 Discovery agent N.A. Investigative [5]
3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 Discovery agent N.A. Investigative [5]
(-)-CATECHINGALLATE DMZOGSK Discovery agent N.A. Investigative [5]
2-Hexadecynoic acid DMTFIPZ Discovery agent N.A. Investigative [54]
GALLOCATECHIN GALLATE DMX2084 Discovery agent N.A. Investigative [5]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [5]
NADPH DM75Q34 Discovery agent N.A. Investigative [55]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Targeting Cyclin-dependent kinase 6 (CDK6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [56]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [57]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [58]
Ribociclib succinate DM9CIUW Breast cancer 2C60-2C65 Approved [59]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [60]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [61]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [62]
GLR2007 DM7DWLY Glioblastoma of brain 2A00.00 Phase 1/2 [63]
FCN-437 DMQ8VUW Breast cancer 2C60-2C65 Phase 1/2 [64]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [65]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cytochrome P450 1B1 (CYP1B1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PINOCEMBRIN DM96VWD N. A. N. A. Phase 2 [1]
Naringenin DMHAZLM N. A. N. A. Phase 1 [1]
Apigenin DMI3491 Discovery agent N.A. Investigative [1]
Kaempferol DMHEMUB Discovery agent N.A. Investigative [1]
ISORHAMNETIN DMQ4Z6E Discovery agent N.A. Investigative [1]
Acacetin DMQOB0X Discovery agent N.A. Investigative [1]
TRISMETHOXYRESVERATROL DM6USPC Discovery agent N.A. Investigative [66]
Galangin DM5TQ2O Discovery agent N.A. Investigative [1]
CHRYSOERIOL DM96ECL Discovery agent N.A. Investigative [1]
DIOSMETIN DM4KXIM Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [2]
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [3]
Cyclin-dependent kinase 6 (CDK6) TTO0FDJ CDK6_HUMAN Inhibitor [4]
Cytochrome P450 1B1 (CYP1B1) TTI84H7 CP1B1_HUMAN Inhibitor [1]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) TTBE4IR Q965D6_PLAFA Inhibitor [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [7]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [7]
UDP-glucuronosyltransferase 1A8 (UGT1A8) DE2GB8N UD18_HUMAN Substrate [7]
UDP-glucuronosyltransferase 1A7 (UGT1A7) DEZO4N3 UD17_HUMAN Substrate [7]

References

1 Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5.
2 Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5.
3 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
4 Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43.
5 Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
6 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
7 Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem. 2004 Jan 9;279(2):1429-41.
8 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
9 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
10 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
11 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
12 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
13 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
14 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
15 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
16 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
17 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
18 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
19 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
20 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
23 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
24 Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
25 Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
26 Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
27 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
28 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
29 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
30 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
31 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
32 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
33 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
34 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
35 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
36 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
37 Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
38 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
39 Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
40 Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
41 Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
42 Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
43 Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
44 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
45 Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
46 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
47 Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
48 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
49 Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
50 ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
51 Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
52 A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
53 Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91.
54 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
55 Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
56 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
57 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
58 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
59 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
60 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
61 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
62 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
63 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
64 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
65 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
66 Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4.